Christian Patricio Camacho-Limas, Department of Medical Oncology, Centro Médico ABC, Mexico City, Mexico
Guillermo Olivares-Beltrán, Department of Medical Oncology, Centro Médico ABC, Mexico City, Mexico
Raquel Gerson-Cwilich, Servicio de Radio-Oncología, Centro Médico ABC, Ciudad de México, México
Alberto Villalobos-Prieto, Department of Medical Oncology, Centro Médico ABC, Mexico City, Mexico
María del Ángel Góngora-Jurado, Clinical Pathology, Centro Médico ABC, Mexico City, Mexico
Alain Sánchez-Rodríguez, Internal Medicine, Centro Médico ABC, Mexico City, Mexico
Objective: Ipilimumab is an antibody for the treatment of metastatic melanoma that currently is scarcely accessible for most cancer centers in Mexico, and this is why a descriptive analysis was carried out in the ABC Hospital, with this being one of the few centers that use this drug in the entire country. Material and methods: A three-year observational study was carried out with the general purpose to describe the clinical course of ipilimumab-treated patients and with the specific purpose to perform an overall survival analysis. Demographic, diagnostic, therapeutic, and clinical variables were analyzed. The response was assessed according to Wolchok’s immune response criteria. Results: Thirteen patients were included, out of which 53% (7/13) were females and 46% (6/13) males, with a median age of 54 years at diagnosis. Median total follow-up of the population was 18 months, and all patients were treated with ipilimumab 3 mg/kg every three weeks for four sessions. Overall survival and progression-free survival had a median of 18 (IQR: 8-24) and 5 (IQR: 4-24) months, respectively. Conclusions: In this cross-sectional cohort analysis, observations on metastatic or recurrent melanoma treatment with ipilimumab published up to now were corroborated. With a response rate of 23%, an essential outcome is a response duration of more than 28 months until current follow-up of the patients who show an objective response with the use of ipilimumab.
Keywords: Melanoma. Ipilimumab. Immunotherapy.
